Feng Su1, Pamela K Green2, Kristin Berry2, George N Ioannou1,2. 1. Division of Gastroenterology/Medicine, Veterans Affairs Puget Sound Health Care System and University of Washington, Seattle, WA. 2. Health Services Research and Development, Veterans Affairs Puget Sound Health Care System, Seattle, WA.
Abstract
Black race and Hispanic ethnicity were associated with lower rates of sustained virologic response (SVR) to interferon-based treatments for chronic hepatitis C virus infection, whereas Asian race was associated with higher SVR rates compared to white patients. We aimed to describe the association between race/ethnicity and effectiveness of new direct-acting antiviral regimens in the Veterans Affairs health care system nationally. We identified 21,095 hepatitis C virus-infected patients (11,029 [52%] white, 6,171 [29%] black, 1,187 [6%] Hispanic, 348 [2%] Asian/Pacific Islander/American Indian/Alaska Native, and 2,360 [11%] declined/missing race or ethnicity) who initiated antiviral treatment with regimens containing sofosbuvir, simeprevir + sofosbuvir, ledipasvir/sofosbuvir, or paritaprevir/ombitasvir/ritonavir/dasabuvir during the 18-month period from January 1, 2014, to June 30, 2015. Overall SVR rates were 89.8% (95% confidence interval [CI] 89.2-90.4) in white, 89.8% (95% CI 89.0-90.6) in black, 86.0% (95% CI 83.7-88.0) in Hispanic, and 90.7% (95% CI 87.0-93.5) in Asian/Pacific Islander/American Indian/Alaska Native patients. However, after adjustment for baseline characteristics, black (adjusted odds ratio = 0.77, P < 0.001) and Hispanic (adjusted odds ratio = 0.76, P = 0.007) patients were less likely to achieve SVR than white patients, a difference that was not explained by early treatment discontinuations. Among genotype 1-infected patients treated with ledipasvir/sofosbuvir monotherapy, black patients had significantly lower SVR than white patients when treated for 8 weeks but not when treated for 12 weeks. CONCLUSION: Direct-acting antivirals produce high SVR rates in white, black, Hispanic, and Asian/Pacific Islander/American Indian/Alaska Native patients; but after adjusting for baseline characteristics, black race and Hispanic ethnicity remain independent predictors of treatment failure. Short 8-week ledipasvir/sofosbuvir monotherapy regimens should perhaps be avoided in black patients with genotype 1 hepatitis C virus. (Hepatology 2017;65:426-438). Published 2016. This article is a U.S. Government work and is in the public domain in the USA.
Black race and Hispanic ethnicity were associated with lower rates of sustained virologic response (SVR) to interferon-based treatments for chronic hepatitis C virus infection, whereas Asian race was associated with higher SVR rates compared to white patients. We aimed to describe the association between race/ethnicity and effectiveness of new direct-acting antiviral regimens in the Veterans Affairs health care system nationally. We identified 21,095 hepatitis C virus-infectedpatients (11,029 [52%] white, 6,171 [29%] black, 1,187 [6%] Hispanic, 348 [2%] Asian/Pacific Islander/American Indian/Alaska Native, and 2,360 [11%] declined/missing race or ethnicity) who initiated antiviral treatment with regimens containing sofosbuvir, simeprevir + sofosbuvir, ledipasvir/sofosbuvir, or paritaprevir/ombitasvir/ritonavir/dasabuvir during the 18-month period from January 1, 2014, to June 30, 2015. Overall SVR rates were 89.8% (95% confidence interval [CI] 89.2-90.4) in white, 89.8% (95% CI 89.0-90.6) in black, 86.0% (95% CI 83.7-88.0) in Hispanic, and 90.7% (95% CI 87.0-93.5) in Asian/Pacific Islander/American Indian/Alaska Native patients. However, after adjustment for baseline characteristics, black (adjusted odds ratio = 0.77, P < 0.001) and Hispanic (adjusted odds ratio = 0.76, P = 0.007) patients were less likely to achieve SVR than white patients, a difference that was not explained by early treatment discontinuations. Among genotype 1-infectedpatients treated with ledipasvir/sofosbuvir monotherapy, black patients had significantly lower SVR than white patients when treated for 8 weeks but not when treated for 12 weeks. CONCLUSION: Direct-acting antivirals produce high SVR rates in white, black, Hispanic, and Asian/Pacific Islander/American Indian/Alaska Native patients; but after adjusting for baseline characteristics, black race and Hispanic ethnicity remain independent predictors of treatment failure. Short 8-week ledipasvir/sofosbuvir monotherapy regimens should perhaps be avoided in black patients with genotype 1 hepatitis C virus. (Hepatology 2017;65:426-438). Published 2016. This article is a U.S. Government work and is in the public domain in the USA.
Authors: Jennifer R Kramer; Thomas P Giordano; Julianne Souchek; Peter Richardson; Lu-Yu Hwang; Hashem B El-Serag Journal: Am J Gastroenterol Date: 2005-01 Impact factor: 10.864
Authors: N Bräu; E J Bini; S Currie; H Shen; W N Schmidt; P D King; S B Ho; R C Cheung; K-Q Hu; B S Anand; F R Simon; A Aytaman; D P Johnson; J A Awad; J Ahmad; C L Mendenhall; M C Pedrosa; R H Moseley; C H Hagedorn; B Waters; K-M Chang; T R Morgan; S J Rossi; L J Jeffers; T L Wright Journal: J Viral Hepat Date: 2006-04 Impact factor: 3.728
Authors: George N Ioannou; Meaghan F Splan; Noel S Weiss; George B McDonald; Laura Beretta; Sum P Lee Journal: Clin Gastroenterol Hepatol Date: 2007-05-16 Impact factor: 11.382
Authors: Louise Geddes; Jenny Iversen; Handan Wand; Aryan Esmaeili; Judith Tsui; Margaret Hellard; Gregory Dore; Jason Grebely; Paul Dietze; Julie Bruneau; Maria Prins; Megan D Morris; Naglaa H Shoukry; Andrew R Lloyd; Arthur Y Kim; Georg Lauer; Andrea L Cox; Kimberly Page; Lisa Maher Journal: Clin Infect Dis Date: 2020-01-01 Impact factor: 9.079
Authors: George N Ioannou; Lauren A Beste; Pamela K Green; Amit G Singal; Elliot B Tapper; Akbar K Waljee; Richard K Sterling; Jordan J Feld; David E Kaplan; Tamar H Taddei; Kristin Berry Journal: Gastroenterology Date: 2019-07-26 Impact factor: 22.682
Authors: Julia L Marcus; Leo B Hurley; Scott Chamberland; Jamila H Champsi; Laura C Gittleman; Daniel G Korn; Jennifer B Lai; Jennifer O Lam; Mary Patricia Pauly; Charles P Quesenberry; Joanna Ready; Varun Saxena; Suk I Seo; David J Witt; Michael J Silverberg Journal: Clin Gastroenterol Hepatol Date: 2018-03-11 Impact factor: 11.382
Authors: Marina Serper; Donna M Evon; Paul W Stewart; Anna S Lok; Jipcy Amador; Bryce B Reeve; Carol E Golin; Michael W Fried; K Rajender Reddy; Richard K Sterling; Souvik Sarkar; Adrian M Di Bisceglie; Joseph K Lim; David R Nelson; Nancy Reau Journal: J Gen Intern Med Date: 2019-10-28 Impact factor: 5.128